Pfizer’s crusade to find its next blockbuster has led to a $725 million deal with San Francisco company Medivation for its Russian allergy drug to fight Alzheimer’s disease.
Merck Serono has joined forces with biopharmaceutical company Ablynx in a deal that could be worth more than 335 million euro to co-develop therapeutic proteins for two targets in oncology and immunology.
Sanofi-aventis’ potential blockbuster Multaq (dronedarone) has been shown to reduce the risk of stroke by more than a third in patients with an irregular heartbeat.